SCHEMBL214647

SCHEMBL214647

NC(=O)c1[nH]cnc1C(=O)N(c1nc2ccccc2[nH]1)c1ccccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.38
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
CYP3A4 P08684 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPK10 P53779 2/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C19 P33261 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
CYP2C9 P11712 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FGFR1 P11362 1/20 0.33
FLT1 P17948 1/20 0.33
LMNA P02545 1/20 0.33
PAX8 Q06710 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214451 0.91 POLB (0.37) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL215204 0.90 KMT2A (0.37) POLBHPGDHTTALDH1A1KDM4E
SCHEMBL214977 0.90 POLB (0.38) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL214715 0.88 POLB (0.40) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL215645 0.87 POLB (0.37) POLBHPGDHTTCYP3A4MAPK10
SCHEMBL214043 0.86 POLB (0.47) POLBALDH1A1MAPK10KDM4ENPC1
SCHEMBL215369 0.86 POLB (0.41) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL214790 0.86 HPGD (0.37) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL214873 0.86 LMNA (0.39) POLBHPGDHTTCYP3A4ALDH1A1
SCHEMBL213713 0.85 NPC1 (0.38) POLBHPGDHTTCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP claimed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885HPGD 3138/4885HTT 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.